Cidara is developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections. The Company’s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to therapies targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California.
Cidara is pursuing an infectious disease-focused development strategy intended to transform standards of care and save lives.
Candidemia and Invasive Candidiasis
Phase 3 Initiated
Candida, PCP and Aspergillus in alloBMT
Flu Prevention & Treatment
RSV, HIV, Other viruses